We could not find any results for:
Make sure your spelling is correct or try broadening your search.
discoverIE Group plc 07 April 2022 7 April 2022 discoverIE Group plc discoverIE Awarded "A" Rating by MSCI ESG discoverIE Group plc (LSE: DSCV, "discoverIE" or the...
("Alcon 3Q Profit Down 18%, Raises 2009 Earnings View 2nd Time," published at 6:12 p.m. EDT, incorrectly included a tax benefit for the latest quarter. The correct version follows.) DOW JONES...
Alcon Inc.'s (ACL) third-quarter profit dropped 18% as foreign-exchange rates took a toll, but the eye-care products giant again raised its 2009 guidance on an improving market. Shares climbed...
-- Alcon takes over development of POT-4 as a treatment for patients with age-related macular degeneration -- Deal provides path for Alcon to acquire Potentia LOUISVILLE, Ky., Oct. 23...
Presentation to be Webcast on September 29, 2009 EMERYVILLE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY) http://www.novabaypharma.com/, a clinical...
Nestle S.A. (NESN.VX) doesn't sees any acquisition opportunities at present, an official said Wednesday. "There's nothing available at the right price," Nestle's head of investor relations said in...
Nestle SA (NESN.VX) said Monday it sees no reason to renegotiate deal terms on eyecare company Alcon Inc. (ACL) with Swiss drugmaker Novartis AG (NVS). "We firmly believe the business continues to...
A panel of medical experts on Friday said a proposed eyedrop drug by River Plate Biotechnology Inc. isn't safe and effective enough to treat patients with dry-eye disease. The panel of medical...
A panel of medical experts on Friday said a proposed eyedrop drug by River Plate Biotechnology Inc. isn't safe and effective enough to treat patients with dry-eye disease. The panel of medical...
The Food and Drug Administration said Wednesday that ISTA Pharmaceutical Inc.'s (ISTA) Bepreve eye drops were effective at treating eye-itching associated with allergies. However, the agency...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions